- Home
- KRMD vs KPTI Comparison
KRMD vs KPTI Comparison
Compare KRMD & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRMD
- KPTI
- Stock Information
- Founded
- KRMD 1980
- KPTI 2008
- Country
- KRMD United States
- KPTI United States
- Employees
- KRMD N/A
- KPTI N/A
- Industry
- KRMD Medical/Dental Instruments
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- KRMD Health Care
- KPTI Health Care
- Exchange
- KRMD Nasdaq
- KPTI Nasdaq
- Market Cap
- KRMD 127.0M
- KPTI 121.2M
- IPO Year
- KRMD N/A
- KPTI 2013
- Fundamental
- Price
- KRMD $2.72
- KPTI $0.86
- Analyst Decision
- KRMD Strong Buy
- KPTI Strong Buy
- Analyst Count
- KRMD 3
- KPTI 4
- Target Price
- KRMD $3.33
- KPTI $5.00
- AVG Volume (30 Days)
- KRMD 96.6K
- KPTI 909.8K
- Earning Date
- KRMD 11-06-2024
- KPTI 10-31-2024
- Dividend Yield
- KRMD N/A
- KPTI N/A
- EPS Growth
- KRMD N/A
- KPTI N/A
- EPS
- KRMD N/A
- KPTI N/A
- Revenue
- KRMD $30,817,017.00
- KPTI $145,668,000.00
- Revenue This Year
- KRMD $15.46
- KPTI $6.41
- Revenue Next Year
- KRMD $17.47
- KPTI $11.85
- P/E Ratio
- KRMD N/A
- KPTI N/A
- Revenue Growth
- KRMD 4.70
- KPTI N/A
- 52 Week Low
- KRMD $1.98
- KPTI $0.62
- 52 Week High
- KRMD $3.09
- KPTI $1.95
- Technical
- Relative Strength Index (RSI)
- KRMD 58.09
- KPTI 58.15
- Support Level
- KRMD $2.42
- KPTI $0.82
- Resistance Level
- KRMD $2.74
- KPTI $0.94
- Average True Range (ATR)
- KRMD 0.14
- KPTI 0.07
- MACD
- KRMD -0.01
- KPTI 0.01
- Stochastic Oscillator
- KRMD 59.41
- KPTI 68.90
About KRMD KORU Medical Systems Inc. (DE)
KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on mechanical infusion products, the FREEDOM Infusion Systems. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, HIgH-Flo Subcutaneous Safety Needle Sets, and Precision Flow Rate Tubing. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.